ACADIA Pharmaceuticals Inc. $ACAD Shares Sold by Royal Bank of Canada

Royal Bank of Canada lowered its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 23.3% during the first quarter, HoldingsChannel reports. The fund owned 223,155 shares of the biopharmaceutical company’s stock after selling 67,699 shares during the period. Royal Bank of Canada’s holdings in ACADIA Pharmaceuticals were worth $4,969,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in ACAD. AQR Capital Management LLC boosted its holdings in ACADIA Pharmaceuticals by 3.8% in the first quarter. AQR Capital Management LLC now owns 67,672 shares of the biopharmaceutical company’s stock valued at $1,124,000 after purchasing an additional 2,492 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in ACADIA Pharmaceuticals by 7.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 89,952 shares of the biopharmaceutical company’s stock worth $1,498,000 after purchasing an additional 6,303 shares in the last quarter. Empowered Funds LLC purchased a new stake in shares of ACADIA Pharmaceuticals during the 1st quarter worth approximately $186,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of ACADIA Pharmaceuticals by 14.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 251,056 shares of the biopharmaceutical company’s stock worth $4,170,000 after buying an additional 31,931 shares during the last quarter. Finally, Intech Investment Management LLC boosted its holdings in shares of ACADIA Pharmaceuticals by 45.6% in the 1st quarter. Intech Investment Management LLC now owns 75,872 shares of the biopharmaceutical company’s stock valued at $1,260,000 after buying an additional 23,766 shares in the last quarter. Institutional investors and hedge funds own 96.71% of the company’s stock.

Insider Transactions at ACADIA Pharmaceuticals

In related news, EVP Elizabeth H.Z. Thompson sold 16,558 shares of ACADIA Pharmaceuticals stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $26.13, for a total value of $432,660.54. Following the transaction, the executive vice president directly owned 18,994 shares in the company, valued at $496,313.22. This trade represents a 46.57% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Mark C. Schneyer sold 14,292 shares of the business’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $29.22, for a total transaction of $417,612.24. Following the completion of the transaction, the executive vice president directly owned 67,828 shares in the company, valued at $1,981,934.16. This represents a 17.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 42,100 shares of company stock worth $1,134,287 over the last 90 days. 26.20% of the stock is currently owned by insiders.

ACADIA Pharmaceuticals Stock Up 0.1%

NASDAQ ACAD opened at $29.45 on Thursday. The firm has a market cap of $5.07 billion, a P/E ratio of 13.27, a P/E/G ratio of 23.16 and a beta of 0.81. ACADIA Pharmaceuticals Inc. has a 52-week low of $19.69 and a 52-week high of $29.85. The business’s 50-day moving average price is $24.88 and its 200 day moving average price is $23.31.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.18 EPS for the quarter, beating the consensus estimate of $0.07 by $0.11. ACADIA Pharmaceuticals had a return on equity of 9.03% and a net margin of 33.42%.The firm had revenue of $308.00 million during the quarter, compared to the consensus estimate of $296.55 million. During the same period in the prior year, the business earned $0.16 EPS. The firm’s revenue was up 16.4% compared to the same quarter last year. As a group, analysts anticipate that ACADIA Pharmaceuticals Inc. will post 0.59 earnings per share for the current year.

Key Headlines Impacting ACADIA Pharmaceuticals

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: Needham raised its price target on ACADIA from $38 to $41 and maintained a “Buy” rating, implying substantial upside from the recent trading level. The higher target reflects increased confidence in the company’s growth outlook. Benzinga
• Positive Sentiment: Citi also initiated or reiterated a Buy view on ACADIA, adding to the favorable analyst sentiment surrounding the company. Citi Buy Recommendation
• Positive Sentiment: Analysts expect Daybue and Nuplazid growth to support ACADIA’s revenue and earnings expansion. The company’s recent quarterly performance also showed year-over-year revenue growth and earnings above consensus estimates, reinforcing the growth narrative. Daybue and Nuplazid Growth Outlook
• Positive Sentiment: ACADIA shares reached a new 12-month high, indicating strong momentum and heightened market interest. The stock is trading above both its 50-day and 200-day moving averages. ACADIA 12-Month High
• Neutral Sentiment: The Q2 earnings call highlighted growth momentum and the company’s commercial opportunities, though investors will continue monitoring execution, product adoption, and upcoming catalysts. ACADIA Earnings Call Highlights
• Neutral Sentiment: Reported short interest was zero, according to the available data, suggesting no measurable short-selling pressure but providing limited additional trading insight.
• Negative Sentiment: RADIANT clinical data introduces uncertainty. While successful results could provide another growth driver, disappointing data could pressure the shares and offset the current analyst optimism. RADIANT Data Risk

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Needham & Company LLC increased their target price on shares of ACADIA Pharmaceuticals from $38.00 to $41.00 and gave the company a “buy” rating in a research report on Wednesday. Wall Street Zen raised shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Citigroup upped their price objective on shares of ACADIA Pharmaceuticals from $35.00 to $39.00 and gave the company a “buy” rating in a research note on Monday. Morgan Stanley set a $27.00 price objective on ACADIA Pharmaceuticals in a report on Monday. Finally, Stifel Nicolaus lifted their target price on ACADIA Pharmaceuticals from $24.00 to $25.00 and gave the stock a “hold” rating in a research report on Tuesday, July 21st. Fourteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, ACADIA Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $33.69.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.